Dentinox Teething Gel is commonly used for the symptomatic management of teething discomfort. This preparation is commonly used to help with supportive symptomatic relief in conditions characterized by periods of heightened symptoms, primarily addressing acute soreness, tenderness, and irritation of the gums.

This localized product is generally applied across domains where additional symptomatic support is needed, particularly when the oral discomfort is significant enough to cause secondary behavioral manifestations like persistent agitation and fussiness. It is relevant for easing symptoms related to inflammatory or irritative states of the gums, and may help patients cope more steadily with difficult episodes. The preparation is generally used in situations where other non-medicinal comfort methods are insufficient to ease distress.

“This application generally contributes to easing distress and supports the child during difficult episodes, helping to maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Oral Discomfort

The gel is relevant for managing symptoms that interfere with daily comfort and may be part of symptomatic management across conditions presenting with acute episodes of localized pain and discomfort.

Regulatory References

1. MHRA advice on lidocaine-containing teething products

Eligibility Map: Who can and cannot use Dentinox Teething Gel

The medicine's eligibility profile is strictly defined by regulatory documents, focusing on age, known sensitivities, and concurrent therapy. This gel is approved for use only in the specified population and is subject to several absolute contraindications and restrictions.

---

Eligibility Status	Applicable Population/Condition
Populations Allowed	Children from 5 months of age for teething discomfort.
Use Restriction	Use is conditional on the failure of non-pharmacological treatments to provide sufficient relief.
Age Restriction	Contraindicated in children under 5 months of age.

---

Absolute Contraindications
Patients with a known hypersensitivity to Lidocaine, Cetylpyridinium Chloride, or any excipients.
Patients with rare hereditary problems of fructose intolerance (due to sorbitol content).
Simultaneous use with any other product containing lidocaine is prohibited.

---

Additional Restrictions: The gel is for short-term use only and must not be used for more than 7 days for each teething episode. Use during pregnancy or lactation is officially stated as not applicable, as the product is indicated solely for infants.

Interactions with other medicines and products

The official regulatory documentation for Dentinox Teething Gel (Lidocaine Hydrochloride and Cetylpyridinium Chloride) states a highly limited interaction profile, which is consistent with its localized application to the gums.

Interaction Scope and Restrictions

Category	Regulatory Statement/Restriction
Systemic Drug-Drug Interactions	None known or formally documented in the Summary of Product Characteristics (SmPC) interaction section.
Interacting Substances	Other medicinal products containing lidocaine.
Interaction Mechanism	Additive effects, resulting in a risk of excess local anesthetic exposure.
Timing-based Rules	No mandatory separation times are documented for administration with other medicines, food, or supplements.
Food, Alcohol, Herbal	No explicit interactions with food, alcohol, or herbal products are documented in the official labeling.

Official Interaction Statements

The most significant interaction-related restriction is a requirement to avoid co-administration with other products containing lidocaine. This measure is in place to prevent the risk of additive pharmacodynamic effects from the local anesthetic component. For interactions with systemically administered medicines, the formal regulatory documentation states that none are known.

This limited structure confirms that the risk profile is confined to localized additive effects rather than complex pharmacokinetic changes involving enzyme systems or transporters.

The physiological action of this preparation involves a dual-action mechanism that focuses on two distinct biological systems: localized nerve conduction blockade and microbial surface destabilization.

Targeted Inhibition of Sensory Nerve Signal Transduction

The component Lidocaine Hydrochloride operates within the domain of peripheral nociceptive signaling by acting as a reversible blocker of voltage-gated sodium channels (NaV) on the membranes of sensory neurons. This mechanistic interference prevents the rapid influx of sodium ions, thereby inhibiting the nerve's ability to propagate an action potential. This interruption of the signal cascade results in a localized cessation of afferent impulse propagation, a physiological change characterized by diminished peripheral neuronal excitability.

Localized Suppression of Oral Microorganism Integrity

The second component, Cetylpyridinium Chloride, engages a non-neural mechanism by acting as a cationic surfactant that induces surface microbial membrane destabilization. Its interaction with the negatively charged components of the bacterial cell membrane leads to structural disruption and increased permeability. This mechanistic domain contributes to the overall physiological consequences by inducing microbial cell lysis and controlling local microorganism viability.

The administration of Dentinox Teething Gel involves a topical regimen applied to the oromucosal surface, specifically the sore area of the infant's gums. The preparation is for use in children from 5 months of age.

Official Administration Protocol

The method for administration involves applying a precise amount: a pea-sized amount of gel, which approximates 0.2 grams per application. This is gently spread onto the affected gum using a clean fingertip or cotton bud. A controlled schedule is followed: a minimum interval of 3 hours must pass between applications, and the total use must not exceed 6 doses within any 24-hour period. If a dose is partially ingested, spat out, or vomited, the full 3-hour waiting period is still required before re-dosing.

Usage of this product is for short-term symptomatic support, with a maximum treatment duration of 7 days for each teething episode, and should cease immediately upon symptom resolution. Its application is restricted to situations where non-pharmacological comfort measures have failed to provide sufficient relief. Furthermore, the concurrent use of Dentinox Teething Gel with any other product that contains lidocaine is prohibited.

Research Evidence / Overview of Studies for Dentinox Teething Gel

Evidence for Use in Teething Discomfort

The medicinal gel, which contains two active components, was studied in research exploring short-term symptom patterns related to teething discomfort. Evidence includes smaller exploratory studies and short-term Randomized Controlled Trials (RCTs), where this type of preparation was evaluated in studies using this type of preparation as a standard treatment against new investigational products. Research has examined outcomes related to physical discomfort in infants and young children.

These studies monitored patient-reported outcomes describing perceived discomfort. Researchers also monitored local gum symptoms, such as redness and swelling, as outcomes describing episodic or acute changes. However, official reviews of this evidence conducted by national regulators describe patterns indicating that the overall evidence available for topical lidocaine products for teething is limited and findings were mixed. The evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly.

Study Design and Methodology

Studies relevant to this product were evaluated in populations consisting mainly of infants and young children exhibiting teething symptoms. Research explored temporary symptoms during the eruption of teeth, with patient ages typically ranging from a few months up to three years. As a result, research focused on episodes where symptoms become more noticeable.

Regulatory Findings and Research Gaps

Official regulatory assessments, which synthesize the entire research landscape, indicate that the evidence quality varies across studies. The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded that the data for oral lidocaine products used for teething are not robust, means they evidence is limited, as regulators require more robust data. The primary research gaps and limitations cited by regulators include the reliance on subjective endpoints, the prevalence of modest sample sizes in relevant studies, and the fact that comparative evidence is lacking for many formulations. Consequently, certainty remains low, and the evidence highlights what is known—and what is still uncertain—about this preparation.

Key Studies & References Oral lidocaine-containing products for infant teething: only to be available under the supervision of a pharmacist (Drug Safety Update)

Common questions about Dentinox Teething Gel (FAQ)

---

Q: Does Dentinox Teething Gel contain benzocaine?

No, official product information identifies the active components as Lidocaine Hydrochloride and Cetylpyridinium Chloride. Benzocaine is not listed as an active ingredient in this formulation.

---

Q: How long does the effect of Dentinox Teething Gel typically last?

Regulatory administration instructions do not specify an exact duration of effect. However, the official protocol requires a minimum interval of 3 hours between applications, if needed. This 3-hour interval is the requirement for safe re-dosing.

---

Q: Does Dentinox Teething Gel interact with paracetamol (acetaminophen)?

Formal regulatory documentation states that no systemic drug-drug interactions are known for this product. The key restriction identified in regulatory documentation is against concurrent use with other products containing the local anesthetic lidocaine.

---

Q: Does Dentinox Teething Gel contain lidocaine?

Yes, Lidocaine Hydrochloride is listed as one of the two active ingredients in the gel. Lidocaine is a local anesthetic intended to provide a temporary, localized numbing effect to help relieve teething pain.

---

Q: What kind of interactions should I be aware of when using this product?

The primary regulatory restriction is the requirement to avoid co-administration with any other medicine or product that contains the local anesthetic lidocaine. This measure is in place to prevent the risk of additive anesthetic effects.

---

Q: Is Dentinox Teething Gel a 'local anesthetic'?

The medicine is officially classified as a Local Anesthetic and Antiseptic Combination. The lidocaine component functions as a local anesthetic, which means it is designed to cause temporary, localized numbing of the affected area.

---

Q: Does this gel contain sugar or alcohol?

The preparation is described as sugar-free, containing Sorbitol and Xylitol. Official regulatory documentation also indicates that it contains a small amount of ethanol (alcohol) derived from an excipient, though this is less than 100 mg per dose.

---

Q: How quickly should I expect to see an effect after applying the gel?

The product's mode of action, which involves the local anesthetic lidocaine, is designed to provide a rapid, temporary numbing effect following application to the irritated gum tissue.

---

Q: Can the gel be used before a baby's first tooth appears?

Official product information states the preparation is licensed solely for the symptomatic relief of discomfort associated with teething in children from 5 months of age. Use is conditional on the age of the child, not the physical presence of a tooth.

---

Q: Does Dentinox Teething Gel have a specific taste or flavor?

Yes, the formulation includes ingredients such as a 'Pharmaceutical Liquid Flavour' and Levomenthol (a mint component), which contribute to the product's taste.

---

Q: Can Dentinox Teething Gel be used for adults with gum pain?

No. The product is indicated solely for the symptomatic management of discomfort associated with the teething process in infants. It is not authorized for use by or in the adult population.

---

Q: Is it okay to store Dentinox Teething Gel in the refrigerator?

Official regulatory storage instructions require that the medicine not be stored above 25 C. Users should ensure their storage location complies with this requirement.

---

Q: Can I apply the gel using a cotton bud instead of my finger?

The approved method for administration involves gently spreading the gel onto the affected gum using a clean fingertip or cotton bud. Both application methods are referenced in the official administration protocol.

---

Q: Can Dentinox Teething Gel cause an upset stomach or diarrhea?

Potential side effects listed in regulatory documents do not specify upset stomach or diarrhea at a known rate. However, official documents note that the excipient Sorbitol can be associated with gastrointestinal effects, particularly for those with rare hereditary problems of fructose intolerance.

---

Q: Do the ingredients include any coloring agents or artificial sweeteners?

Yes, the ingredients include the coloring agent Caramel (E150). The preparation is also sweetened with Sorbitol and Sodium Saccharin, which are non-sugar sweeteners.

---

Q: Can the gel be used on sore spots in the mouth that aren't related to teething?

The medicine is indicated solely for the symptomatic relief of discomfort associated with the teething process in infants. Official documents restrict its use to this specific condition.

---

Q: What should I do if my baby reacts badly to the gel?

If a severe allergic reaction (hypersensitivity) occurs, such as a rash or swelling of the face, neck, tongue, or throat, regulatory guidance states that users should seek medical attention immediately and discontinue use of the product.

How to Store and Dispose of Dentinox Teething Gel?

This medicine must be stored and disposed of according to the official regulatory instructions to ensure stability and environmental compliance.

Storage Scope	Requirement
Temperature Maximum	Do not store above 25 C
Child Safety	Keep out of the reach and sight of children
In-Use Stability	Shelf life after opening is 1 year
Container Rule	Store the product tightly closed in the original folding box

All stability constraints must be observed: the gel must not be used after the expiry date. For disposal, the medicine should not be thrown away in waste-water or with household waste. Instead, regulatory guidance instructs users to ask a pharmacist for the proper method of disposing of unused or expired medication.